NCBI Home Page NCBI Site Search page NCBI Guide that lists and describes the NCBI resources
Conserved domains on  [gi|194306629|ref|NP_001123612|]
View 

endoplasmic reticulum aminopeptidase 2 isoform 1 [Homo sapiens]

Protein Classification

M1 family metallopeptidase( domain architecture ID 10176184)

M1 family metallopeptidase containing an ERAP1-like C-terminal domain with HEAT-like repeats is a zinc-dependent metallopeptidase with an HEXXH motif as part of its active site, similar to aminopeptidase N, a broad specificity aminopeptidase, and glutamyl aminopeptidase, which releases N-terminal glutamate from a peptide

EC:  3.4.11.-
Gene Ontology:  GO:0008237|GO:0008270|GO:0006508
MEROPS:  M1

Graphical summary

 Zoom to residue level

show extra options »

Show site features     Horizontal zoom: ×

List of domain hits

Name Accession Description Interval E-value
M1_APN-Q_like cd09601
Peptidase M1 aminopeptidase N catalytic domain family which includes aminopeptidase N (APN), ...
76-543 0e+00

Peptidase M1 aminopeptidase N catalytic domain family which includes aminopeptidase N (APN), aminopeptidase Q (APQ), tricorn interacting factor F3, and endoplasmic reticulum aminopeptidase 1 (ERAP1); This M1 peptidase family includes eukaryotic and bacterial members: the catalytic domains of aminopeptidase N (APN), aminopeptidase Q (APQ, laeverin), endoplasmic reticulum aminopeptidase 1 (ERAP1) as well as tricorn interacting factor F3. Aminopeptidase N (APN; CD13; alanyl aminopeptidase; EC 3.4.11.2), a type II integral membrane protease, preferentially cleaves neutral amino acids from the N-terminus of oligopeptides and is present in a variety of human tissues and cell types (leukocyte, fibroblast, endothelial and epithelial cells). APN expression is dysregulated in inflammatory diseases such as chronic pain, rheumatoid arthritis, multiple sclerosis, systemic sclerosis, systemic lupus erythematosus, polymyositis/dermatomyosytis and pulmonary sarcoidosis, and is enhanced in tumor cells such as melanoma, renal, prostate, pancreas, colon, gastric and thyroid cancers. It is considered a marker of differentiation since it is predominantly expressed on stem cells and on cells of the granulocytic and monocytic lineages at distinct stages of differentiation. Thus, APN inhibition may lead to the development of anti-cancer and anti-inflammatory drugs. ERAP1, also known as endoplasmic reticulum aminopeptidase associated with antigen processing (ERAAP), adipocyte derived leucine aminopeptidase (A-LAP), or aminopeptidase regulating tumor necrosis factor receptor I (THFRI) shedding (ARTS-1), associates with the closely related ER aminopeptidase ERAP2, for the final trimming of peptides within the ER for presentation by MHC class I molecules. ERAP1 is associated with ankylosing spondylitis (AS), an inflammatory arthritis that predominantly affects the spine. ERAP1 also aids in the shedding of membrane-bound cytokine receptors. The tricorn interacting factor F3, together with factors F1 and F2, degrades the tricorn protease products, producing free amino acids, thus completing the proteasomal degradation pathway. F3 is homologous to F2, but not F1, and shows a strong preference for glutamate in the P1' position. APQ, also known as laeverin, is specifically expressed in human embryo-derived extravillous trophoblasts (EVTs) that invade the uterus during early placentation. It cleaves the N-terminal amino acid of various peptides such as angiotensin III, endokinin C, and kisspeptin-10, all expressed in the placenta in large quantities. APN is a receptor for coronaviruses, although the virus receptor interaction site seems to be distinct from the enzymatic site and aminopeptidase activity is not necessary for viral infection. APNs are also putative Cry toxin receptors. Cry1 proteins are pore-forming toxins that bind to the midgut epithelial cell membrane of susceptible insect larvae, causing extensive damage. Several different toxins, including Cry1Aa, Cry1Ab, Cry1Ac, Cry1Ba, Cry1Ca and Cry1Fa, have been shown to bind to APNs; however, a direct role of APN in cytotoxicity has been yet to be firmly established.


:

Pssm-ID: 341064 [Multi-domain]  Cd Length: 442  Bit Score: 629.23  E-value: 0e+00
                         10        20        30        40        50        60        70        80
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 194306629  76 LHYDLFVHPNLTSLDFVASEKIEVLVSNATQFIILHSKDLEITNATLQSEEDsrymKPGKELKVLSYPAHEQIALLVPEK 155
Cdd:cd09601    1 LHYDLTLTPDLENFTFSGSVTITLEVLEPTDTIVLHAKDLTITSASLTLKGG----SGIIEVTVVTDEETEFLTITLDET 76
                         90       100       110       120       130       140       150       160
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 194306629 156 LTPHLKYYVAMDFQAKLGDGFEGFYKSTYRTLGGETRILAVTDFEPTQARMAFPCFDEPLFKANFSIKIRRESRHIALSN 235
Cdd:cd09601   77 LPPGENYTLSIEFTGKLNDDLRGFYRSSYTDEDGETRYLAATQFEPTDARRAFPCFDEPAFKATFDITITHPKGYTALSN 156
                        170       180       190       200       210       220       230       240
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 194306629 236 MPKVKTIELEGGLLEDHFETTVKMSTYLVAYIVCDFHSLSGFTSSGVKVSIYASPDKRNQTHYALQASLKLLDFYEKYFD 315
Cdd:cd09601  157 MPPVESTELEDGWKTTTFETTPPMSTYLVAFVVGDFEYIESTTKSGVPVRVYARPGKIEQGDFALEVAPKILDFYEDYFG 236
                        250       260       270       280       290       300       310       320
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 194306629 316 IYYPLSKLDLIAIPDFAPGAMENWGLITYRETSLLFDPKTSSASDKLWVTRVIAHELAHQWFGNLVTMEWWNDIWLKEGF 395
Cdd:cd09601  237 IPYPLPKLDLVAIPDFAAGAMENWGLITYRETALLYDPKTSSASDKQRVAEVIAHELAHQWFGNLVTMKWWDDLWLNEGF 316
                        330       340       350       360       370       380       390       400
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 194306629 396 AKYMELIAVNATYPELQFDDYFL-NVCFEVITKDSLNSSRPISKPAETPTQIQEMFDEVSYNKGACILNMLKDFLGEEKF 474
Cdd:cd09601  317 ATYMEYLAVDKLFPEWNMWDQFVvDELQSALELDSLASSHPIEVPVESPSEISEIFDAISYSKGASVLRMLENFLGEEVF 396
                        410       420       430       440       450       460
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....
gi 194306629 475 QKGIIQYLKKFSYRNAKNDDLWSSLSNSCLESdftsggvchsdpkmtsnmlaflgENAEVKEMMTTWTL 543
Cdd:cd09601  397 RKGLRKYLKKHAYGNATTDDLWEALQEASGES-----------------------KPLDVKEIMDSWTL 442
ERAP1_C pfam11838
ERAP1-like C-terminal domain; This large domain is composed of 16 alpha helices organized as 8 ...
620-938 2.81e-84

ERAP1-like C-terminal domain; This large domain is composed of 16 alpha helices organized as 8 HEAT-like repeats. This domain forms a concave face that faces towards the active site of the peptidase.


:

Pssm-ID: 463368 [Multi-domain]  Cd Length: 316  Bit Score: 274.15  E-value: 2.81e-84
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 194306629  620 WVKFNVDSNGYYIVHYEGHGWDQLITQLNqnHTLLRPKDRVGLIHDVFQLVGAGRLTLDKALDMTYYLQHETSSPALLEG 699
Cdd:pfam11838   1 WVKLNADDTGYYRVNYDPESLAALLEQLL--SKVLSPLDRAGLIDDAFALARAGELSTSDALDLVLAYLNETDYVVWSAA 78
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 194306629  700 LSYLESFYHMMDRrniSDISENLKRYLLQYFKPVIDRQSWSDKG--SVWDRMLRSALLKLACDLNHAPCIQKAAELFSQW 777
Cdd:pfam11838  79 LSQLSTLRSLLSA---DPEYEALKAFLRKLLSPLAEKLGWEAPPgeSHLDRQLRALLLSAACSAGDPECVAEAKKLFDAW 155
                         170       180       190       200       210       220       230       240
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 194306629  778 MEssGKLNIPTDVLKIVYSVGAQ--TTAGWNYLLEQYELSMSSAEQNKILYALSTSKHQEKLLKLIELGMEGKVIKTQNL 855
Cdd:pfam11838 156 LD--GDDAIPPDLRWAVYCAAVAngGEAEWDALLERYRDTTSPSEKERALRALAATPDPELLQRALELALDSDEVRNQDL 233
                         250       260       270       280       290       300       310       320
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 194306629  856 AALLHAIARRPKGQQLAWDFVRENWTHLLKKFDLGSYdIRMIISGTTAHFSSKDKLQEVKLFFESLEAQGSHLdIFQTVL 935
Cdd:pfam11838 234 RAVIAGLASNPAGRDLAWDFVKENWDALVKRLGGGSS-LGRLVKGLTPSFSTEEELDEVEAFFADKDTPGLRR-ALAQAL 311

                  ...
gi 194306629  936 ETI 938
Cdd:pfam11838 312 ETI 314
 
Name Accession Description Interval E-value
M1_APN-Q_like cd09601
Peptidase M1 aminopeptidase N catalytic domain family which includes aminopeptidase N (APN), ...
76-543 0e+00

Peptidase M1 aminopeptidase N catalytic domain family which includes aminopeptidase N (APN), aminopeptidase Q (APQ), tricorn interacting factor F3, and endoplasmic reticulum aminopeptidase 1 (ERAP1); This M1 peptidase family includes eukaryotic and bacterial members: the catalytic domains of aminopeptidase N (APN), aminopeptidase Q (APQ, laeverin), endoplasmic reticulum aminopeptidase 1 (ERAP1) as well as tricorn interacting factor F3. Aminopeptidase N (APN; CD13; alanyl aminopeptidase; EC 3.4.11.2), a type II integral membrane protease, preferentially cleaves neutral amino acids from the N-terminus of oligopeptides and is present in a variety of human tissues and cell types (leukocyte, fibroblast, endothelial and epithelial cells). APN expression is dysregulated in inflammatory diseases such as chronic pain, rheumatoid arthritis, multiple sclerosis, systemic sclerosis, systemic lupus erythematosus, polymyositis/dermatomyosytis and pulmonary sarcoidosis, and is enhanced in tumor cells such as melanoma, renal, prostate, pancreas, colon, gastric and thyroid cancers. It is considered a marker of differentiation since it is predominantly expressed on stem cells and on cells of the granulocytic and monocytic lineages at distinct stages of differentiation. Thus, APN inhibition may lead to the development of anti-cancer and anti-inflammatory drugs. ERAP1, also known as endoplasmic reticulum aminopeptidase associated with antigen processing (ERAAP), adipocyte derived leucine aminopeptidase (A-LAP), or aminopeptidase regulating tumor necrosis factor receptor I (THFRI) shedding (ARTS-1), associates with the closely related ER aminopeptidase ERAP2, for the final trimming of peptides within the ER for presentation by MHC class I molecules. ERAP1 is associated with ankylosing spondylitis (AS), an inflammatory arthritis that predominantly affects the spine. ERAP1 also aids in the shedding of membrane-bound cytokine receptors. The tricorn interacting factor F3, together with factors F1 and F2, degrades the tricorn protease products, producing free amino acids, thus completing the proteasomal degradation pathway. F3 is homologous to F2, but not F1, and shows a strong preference for glutamate in the P1' position. APQ, also known as laeverin, is specifically expressed in human embryo-derived extravillous trophoblasts (EVTs) that invade the uterus during early placentation. It cleaves the N-terminal amino acid of various peptides such as angiotensin III, endokinin C, and kisspeptin-10, all expressed in the placenta in large quantities. APN is a receptor for coronaviruses, although the virus receptor interaction site seems to be distinct from the enzymatic site and aminopeptidase activity is not necessary for viral infection. APNs are also putative Cry toxin receptors. Cry1 proteins are pore-forming toxins that bind to the midgut epithelial cell membrane of susceptible insect larvae, causing extensive damage. Several different toxins, including Cry1Aa, Cry1Ab, Cry1Ac, Cry1Ba, Cry1Ca and Cry1Fa, have been shown to bind to APNs; however, a direct role of APN in cytotoxicity has been yet to be firmly established.


Pssm-ID: 341064 [Multi-domain]  Cd Length: 442  Bit Score: 629.23  E-value: 0e+00
                         10        20        30        40        50        60        70        80
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 194306629  76 LHYDLFVHPNLTSLDFVASEKIEVLVSNATQFIILHSKDLEITNATLQSEEDsrymKPGKELKVLSYPAHEQIALLVPEK 155
Cdd:cd09601    1 LHYDLTLTPDLENFTFSGSVTITLEVLEPTDTIVLHAKDLTITSASLTLKGG----SGIIEVTVVTDEETEFLTITLDET 76
                         90       100       110       120       130       140       150       160
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 194306629 156 LTPHLKYYVAMDFQAKLGDGFEGFYKSTYRTLGGETRILAVTDFEPTQARMAFPCFDEPLFKANFSIKIRRESRHIALSN 235
Cdd:cd09601   77 LPPGENYTLSIEFTGKLNDDLRGFYRSSYTDEDGETRYLAATQFEPTDARRAFPCFDEPAFKATFDITITHPKGYTALSN 156
                        170       180       190       200       210       220       230       240
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 194306629 236 MPKVKTIELEGGLLEDHFETTVKMSTYLVAYIVCDFHSLSGFTSSGVKVSIYASPDKRNQTHYALQASLKLLDFYEKYFD 315
Cdd:cd09601  157 MPPVESTELEDGWKTTTFETTPPMSTYLVAFVVGDFEYIESTTKSGVPVRVYARPGKIEQGDFALEVAPKILDFYEDYFG 236
                        250       260       270       280       290       300       310       320
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 194306629 316 IYYPLSKLDLIAIPDFAPGAMENWGLITYRETSLLFDPKTSSASDKLWVTRVIAHELAHQWFGNLVTMEWWNDIWLKEGF 395
Cdd:cd09601  237 IPYPLPKLDLVAIPDFAAGAMENWGLITYRETALLYDPKTSSASDKQRVAEVIAHELAHQWFGNLVTMKWWDDLWLNEGF 316
                        330       340       350       360       370       380       390       400
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 194306629 396 AKYMELIAVNATYPELQFDDYFL-NVCFEVITKDSLNSSRPISKPAETPTQIQEMFDEVSYNKGACILNMLKDFLGEEKF 474
Cdd:cd09601  317 ATYMEYLAVDKLFPEWNMWDQFVvDELQSALELDSLASSHPIEVPVESPSEISEIFDAISYSKGASVLRMLENFLGEEVF 396
                        410       420       430       440       450       460
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....
gi 194306629 475 QKGIIQYLKKFSYRNAKNDDLWSSLSNSCLESdftsggvchsdpkmtsnmlaflgENAEVKEMMTTWTL 543
Cdd:cd09601  397 RKGLRKYLKKHAYGNATTDDLWEALQEASGES-----------------------KPLDVKEIMDSWTL 442
PepN COG0308
Aminopeptidase N, contains DUF3458 domain [Amino acid transport and metabolism];
68-623 7.21e-118

Aminopeptidase N, contains DUF3458 domain [Amino acid transport and metabolism];


Pssm-ID: 440077 [Multi-domain]  Cd Length: 609  Bit Score: 373.59  E-value: 7.21e-118
                         10        20        30        40        50        60        70        80
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 194306629  68 RLPSVVIPLHYDLFVHPNLTSLDFVASEKIEVLV-SNATQFIILHSKDLEITNATLQseedsrymkpGKELKVLSypAHE 146
Cdd:COG0308   10 YRPPGYDVTHYDLDLDLDPATTRLSGTATITFTAtEAPLDSLVLDLKGLEVTSVTVD----------GKPLDFTR--DGE 77
                         90       100       110       120       130       140       150       160
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 194306629 147 QIALLVPEKLTPHLKYYVAMDFQAKLGDGFEGFYKSTYRtlgGETRILAVTDFEPTQARMAFPCFDEPLFKANFSIKIRR 226
Cdd:COG0308   78 RLTITLPKPLAPGETFTLEIEYSGKPSNGGEGLYRSGDP---PDGPPYLYTQCEPEGARRWFPCFDHPDDKATFTLTVTV 154
                        170       180       190       200       210       220       230       240
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 194306629 227 ESRHIALSNMPKVKTIELEGGLLEDHFETTVKMSTYLVAYIVCDFHSLSGFTSSGVKVSIYASPDKRNQTHYALQASLKL 306
Cdd:COG0308  155 PAGWVAVSNGNLVSETELGDGRTTWHWADTQPIPTYLFALAAGDYAVVEDTFASGVPLRVYVRPGLADKAKEAFESTKRM 234
                        250       260       270       280       290       300       310       320
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 194306629 307 LDFYEKYFDIYYPLSKLDLIAIPDFAPGAMENWGLITYRETsLLFDpKTSSASDKLWVTRVIAHELAHQWFGNLVTMEWW 386
Cdd:COG0308  235 LDFFEELFGVPYPFDKYDQVAVPDFNFGAMENQGLVTFGEK-VLAD-ETATDADYERRESVIAHELAHQWFGNLVTCADW 312
                        330       340       350       360       370       380       390       400
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 194306629 387 NDIWLKEGFAKYMELIAVNATYPELQFDDYFLNVCFEV-ITKDSLNSSRPISkpAETPTQIQEMFDEVSYNKGACILNML 465
Cdd:COG0308  313 DDLWLNEGFATYMEQLFSEDLYGKDAADRIFVGALRSYaFAEDAGPNAHPIR--PDDYPEIENFFDGIVYEKGALVLHML 390
                        410       420       430       440       450       460       470       480
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 194306629 466 KDFLGEEKFQKGIIQYLKKFSYRNAKNDDLWSSLSNsclesdfTSGgvchsdpkmtsnmlaflgenAEVKEMMTTWTLQK 545
Cdd:COG0308  391 RTLLGDEAFRAGLRLYFARHAGGNATTEDFLAALEE-------ASG--------------------RDLSAFFDQWLYQA 443
                        490       500       510       520       530       540       550       560
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 194306629 546 GIPLLVVK-----QDGCSLRLQQERFlqgvfqedpewralqERYLWHIPLTYSTSSSNVIHRHILKSKTDTlDLPEKTSW 620
Cdd:COG0308  444 GLPTLEVEyeydaDGKVTLTLRQTPP---------------RPHPFHIPLEVGLLGGKLTARTVLLDGEQT-ELVAKPDP 507

                 ...
gi 194306629 621 VKF 623
Cdd:COG0308  508 VLL 510
Peptidase_M1 pfam01433
Peptidase family M1 domain; Members of this family are aminopeptidases. The members differ ...
298-500 3.25e-93

Peptidase family M1 domain; Members of this family are aminopeptidases. The members differ widely in specificity, hydrolysing acidic, basic or neutral N-terminal residues. This family includes leukotriene-A4 hydrolase, this enzyme also has an aminopeptidase activity.


Pssm-ID: 426262 [Multi-domain]  Cd Length: 219  Bit Score: 294.20  E-value: 3.25e-93
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 194306629  298 YALQASLKLLDFYEKYFDIYYPLSKLDLIAIPDFAPGAMENWGLITYRETSLLFDPKTSSASDKLWVTRVIAHELAHQWF 377
Cdd:pfam01433   1 YALEITVKLLEFYEDYFNIPYPLPKYDLVALPDFSAGAMENWGLITYRETLLLYDPGNSSTSDKQRVASVIAHELAHQWF 80
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 194306629  378 GNLVTMEWWNDIWLKEGFAKYMELIAVNATYPELQF-DDYFLNVCFEVITKDSLNSSRPISKPAETPTQIQEMFDEVSYN 456
Cdd:pfam01433  81 GNLVTMKWWDDLWLNEGFATYMEYLGTDALFPEWNIwEQFLLDEVQNAMARDALDSSHPITQNVNDPSEIDDIFDAIPYE 160
                         170       180       190       200
                  ....*....|....*....|....*....|....*....|....
gi 194306629  457 KGACILNMLKDFLGEEKFQKGIIQYLKKFSYRNAKNDDLWSSLS 500
Cdd:pfam01433 161 KGASVLRMLETLLGEEVFQKGLRSYLKKFQYGNATTEDLWDALS 204
ERAP1_C pfam11838
ERAP1-like C-terminal domain; This large domain is composed of 16 alpha helices organized as 8 ...
620-938 2.81e-84

ERAP1-like C-terminal domain; This large domain is composed of 16 alpha helices organized as 8 HEAT-like repeats. This domain forms a concave face that faces towards the active site of the peptidase.


Pssm-ID: 463368 [Multi-domain]  Cd Length: 316  Bit Score: 274.15  E-value: 2.81e-84
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 194306629  620 WVKFNVDSNGYYIVHYEGHGWDQLITQLNqnHTLLRPKDRVGLIHDVFQLVGAGRLTLDKALDMTYYLQHETSSPALLEG 699
Cdd:pfam11838   1 WVKLNADDTGYYRVNYDPESLAALLEQLL--SKVLSPLDRAGLIDDAFALARAGELSTSDALDLVLAYLNETDYVVWSAA 78
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 194306629  700 LSYLESFYHMMDRrniSDISENLKRYLLQYFKPVIDRQSWSDKG--SVWDRMLRSALLKLACDLNHAPCIQKAAELFSQW 777
Cdd:pfam11838  79 LSQLSTLRSLLSA---DPEYEALKAFLRKLLSPLAEKLGWEAPPgeSHLDRQLRALLLSAACSAGDPECVAEAKKLFDAW 155
                         170       180       190       200       210       220       230       240
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 194306629  778 MEssGKLNIPTDVLKIVYSVGAQ--TTAGWNYLLEQYELSMSSAEQNKILYALSTSKHQEKLLKLIELGMEGKVIKTQNL 855
Cdd:pfam11838 156 LD--GDDAIPPDLRWAVYCAAVAngGEAEWDALLERYRDTTSPSEKERALRALAATPDPELLQRALELALDSDEVRNQDL 233
                         250       260       270       280       290       300       310       320
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 194306629  856 AALLHAIARRPKGQQLAWDFVRENWTHLLKKFDLGSYdIRMIISGTTAHFSSKDKLQEVKLFFESLEAQGSHLdIFQTVL 935
Cdd:pfam11838 234 RAVIAGLASNPAGRDLAWDFVKENWDALVKRLGGGSS-LGRLVKGLTPSFSTEEELDEVEAFFADKDTPGLRR-ALAQAL 311

                  ...
gi 194306629  936 ETI 938
Cdd:pfam11838 312 ETI 314
pepN_strep_liv TIGR02412
aminopeptidase N, Streptomyces lividans type; This family is a subset of the members of the ...
197-503 8.50e-60

aminopeptidase N, Streptomyces lividans type; This family is a subset of the members of the zinc metallopeptidase family M1 (pfam01433), with a single member characterized in Streptomyces lividans 66 and designated aminopeptidase N. The spectrum of activity may differ somewhat from the aminopeptidase N clade of E. coli and most other Proteobacteria, well separated phylogenetically within the M1 family. The M1 family also includes leukotriene A-4 hydrolase/aminopeptidase (with a bifunctional active site).


Pssm-ID: 274121 [Multi-domain]  Cd Length: 831  Bit Score: 220.05  E-value: 8.50e-60
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 194306629  197 TDFEPTQARMAFPCFDEPLFKANFSIKIRRESRHIALSNMPKVKTIELEGGLLEDhFETTVKMSTYLVAYIVCDFHSLSG 276
Cdd:TIGR02412 122 TQFEPADARRVFAVFDQPDLKANFKFSVKAPEDWTVISNSRETDVTPEPADRRWE-FPETPKLSTYLTAVAAGPYHSVQD 200
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 194306629  277 fTSSGVKVSIYASPDKRNQ--THYALQASLKLLDFYEKYFDIYYPLSKLDLIAIPDFAPGAMENWGLITYRETSLLFDPK 354
Cdd:TIGR02412 201 -ESRSYPLGIYARRSLAQYldADAIFTITRQGLAFFHRKFGYPYPFKKYDQIFVPEFNAGAMENAGCVTFAENFLHRAEA 279
                         170       180       190       200       210       220       230       240
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 194306629  355 TSSASDKLwvTRVIAHELAHQWFGNLVTMEWWNDIWLKEGFAKYME-LIAVNATYPELQFDDYFLNVCFEVITKDSLNSS 433
Cdd:TIGR02412 280 TRAEKENR--AGVILHEMAHMWFGDLVTMRWWNDLWLNESFAEYMGtLASAEATEYTDAWTTFAAQGKQWAYEADQLPTT 357
                         250       260       270       280       290       300       310
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 194306629  434 RPISKPAETPTQIQEMFDEVSYNKGACILNMLKDFLGEEKFQKGIIQYLKKFSYRNAKNDDLWSSLSNSC 503
Cdd:TIGR02412 358 HPIVADVADLADALSNFDGITYAKGASVLKQLVAWVGEEAFFAGVNAYFKRHAFGNATLDDLIDSLAKAS 427
pepN PRK14015
aminopeptidase N; Provisional
233-485 5.47e-12

aminopeptidase N; Provisional


Pssm-ID: 237585 [Multi-domain]  Cd Length: 875  Bit Score: 69.77  E-value: 5.47e-12
                         10        20        30        40        50        60        70        80
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 194306629 233 LSNMPKVKTIELEGGLledHFET----TVKMStYLVAYIVCDFHSLS-GF-TSSG--VKVSIYASPDKRNQTHYALQaSL 304
Cdd:PRK14015 161 LSNGNLVESGELPDGR---HWATwedpFPKPS-YLFALVAGDLDVLEdTFtTRSGreVALEIYVEPGNLDKCDHAMD-SL 235
                         90       100       110       120       130       140       150       160
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 194306629 305 K---LLDfyEKYFDIYYPLSKLDLIAIPDFAPGAMENWGL-I---TYretsLLFDPKTSSASDKLWVTRVIAHELAHQWF 377
Cdd:PRK14015 236 KksmKWD--EERFGLEYDLDIFMIVAVDDFNMGAMENKGLnIfnsKY----VLADPETATDADYERIESVIAHEYFHNWT 309
                        170       180       190       200       210       220       230       240
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 194306629 378 GNLVTMEWWNDIWLKEGFAKY--------MELIAVN-----ATYPELQFDDyflnvcfevitkDSLNSSRPISkpaetPT 444
Cdd:PRK14015 310 GNRVTCRDWFQLSLKEGLTVFrdqefsadLGSRAVKriedvRVLRAAQFAE------------DAGPMAHPVR-----PD 372
                        250       260       270       280
                 ....*....|....*....|....*....|....*....|....
gi 194306629 445 QIQEM--FDEVS-YNKGACILNMLKDFLGEEKFQKGIIQYLKKF 485
Cdd:PRK14015 373 SYIEInnFYTATvYEKGAEVIRMLHTLLGEEGFRKGMDLYFERH 416
 
Name Accession Description Interval E-value
M1_APN-Q_like cd09601
Peptidase M1 aminopeptidase N catalytic domain family which includes aminopeptidase N (APN), ...
76-543 0e+00

Peptidase M1 aminopeptidase N catalytic domain family which includes aminopeptidase N (APN), aminopeptidase Q (APQ), tricorn interacting factor F3, and endoplasmic reticulum aminopeptidase 1 (ERAP1); This M1 peptidase family includes eukaryotic and bacterial members: the catalytic domains of aminopeptidase N (APN), aminopeptidase Q (APQ, laeverin), endoplasmic reticulum aminopeptidase 1 (ERAP1) as well as tricorn interacting factor F3. Aminopeptidase N (APN; CD13; alanyl aminopeptidase; EC 3.4.11.2), a type II integral membrane protease, preferentially cleaves neutral amino acids from the N-terminus of oligopeptides and is present in a variety of human tissues and cell types (leukocyte, fibroblast, endothelial and epithelial cells). APN expression is dysregulated in inflammatory diseases such as chronic pain, rheumatoid arthritis, multiple sclerosis, systemic sclerosis, systemic lupus erythematosus, polymyositis/dermatomyosytis and pulmonary sarcoidosis, and is enhanced in tumor cells such as melanoma, renal, prostate, pancreas, colon, gastric and thyroid cancers. It is considered a marker of differentiation since it is predominantly expressed on stem cells and on cells of the granulocytic and monocytic lineages at distinct stages of differentiation. Thus, APN inhibition may lead to the development of anti-cancer and anti-inflammatory drugs. ERAP1, also known as endoplasmic reticulum aminopeptidase associated with antigen processing (ERAAP), adipocyte derived leucine aminopeptidase (A-LAP), or aminopeptidase regulating tumor necrosis factor receptor I (THFRI) shedding (ARTS-1), associates with the closely related ER aminopeptidase ERAP2, for the final trimming of peptides within the ER for presentation by MHC class I molecules. ERAP1 is associated with ankylosing spondylitis (AS), an inflammatory arthritis that predominantly affects the spine. ERAP1 also aids in the shedding of membrane-bound cytokine receptors. The tricorn interacting factor F3, together with factors F1 and F2, degrades the tricorn protease products, producing free amino acids, thus completing the proteasomal degradation pathway. F3 is homologous to F2, but not F1, and shows a strong preference for glutamate in the P1' position. APQ, also known as laeverin, is specifically expressed in human embryo-derived extravillous trophoblasts (EVTs) that invade the uterus during early placentation. It cleaves the N-terminal amino acid of various peptides such as angiotensin III, endokinin C, and kisspeptin-10, all expressed in the placenta in large quantities. APN is a receptor for coronaviruses, although the virus receptor interaction site seems to be distinct from the enzymatic site and aminopeptidase activity is not necessary for viral infection. APNs are also putative Cry toxin receptors. Cry1 proteins are pore-forming toxins that bind to the midgut epithelial cell membrane of susceptible insect larvae, causing extensive damage. Several different toxins, including Cry1Aa, Cry1Ab, Cry1Ac, Cry1Ba, Cry1Ca and Cry1Fa, have been shown to bind to APNs; however, a direct role of APN in cytotoxicity has been yet to be firmly established.


Pssm-ID: 341064 [Multi-domain]  Cd Length: 442  Bit Score: 629.23  E-value: 0e+00
                         10        20        30        40        50        60        70        80
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 194306629  76 LHYDLFVHPNLTSLDFVASEKIEVLVSNATQFIILHSKDLEITNATLQSEEDsrymKPGKELKVLSYPAHEQIALLVPEK 155
Cdd:cd09601    1 LHYDLTLTPDLENFTFSGSVTITLEVLEPTDTIVLHAKDLTITSASLTLKGG----SGIIEVTVVTDEETEFLTITLDET 76
                         90       100       110       120       130       140       150       160
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 194306629 156 LTPHLKYYVAMDFQAKLGDGFEGFYKSTYRTLGGETRILAVTDFEPTQARMAFPCFDEPLFKANFSIKIRRESRHIALSN 235
Cdd:cd09601   77 LPPGENYTLSIEFTGKLNDDLRGFYRSSYTDEDGETRYLAATQFEPTDARRAFPCFDEPAFKATFDITITHPKGYTALSN 156
                        170       180       190       200       210       220       230       240
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 194306629 236 MPKVKTIELEGGLLEDHFETTVKMSTYLVAYIVCDFHSLSGFTSSGVKVSIYASPDKRNQTHYALQASLKLLDFYEKYFD 315
Cdd:cd09601  157 MPPVESTELEDGWKTTTFETTPPMSTYLVAFVVGDFEYIESTTKSGVPVRVYARPGKIEQGDFALEVAPKILDFYEDYFG 236
                        250       260       270       280       290       300       310       320
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 194306629 316 IYYPLSKLDLIAIPDFAPGAMENWGLITYRETSLLFDPKTSSASDKLWVTRVIAHELAHQWFGNLVTMEWWNDIWLKEGF 395
Cdd:cd09601  237 IPYPLPKLDLVAIPDFAAGAMENWGLITYRETALLYDPKTSSASDKQRVAEVIAHELAHQWFGNLVTMKWWDDLWLNEGF 316
                        330       340       350       360       370       380       390       400
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 194306629 396 AKYMELIAVNATYPELQFDDYFL-NVCFEVITKDSLNSSRPISKPAETPTQIQEMFDEVSYNKGACILNMLKDFLGEEKF 474
Cdd:cd09601  317 ATYMEYLAVDKLFPEWNMWDQFVvDELQSALELDSLASSHPIEVPVESPSEISEIFDAISYSKGASVLRMLENFLGEEVF 396
                        410       420       430       440       450       460
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....
gi 194306629 475 QKGIIQYLKKFSYRNAKNDDLWSSLSNSCLESdftsggvchsdpkmtsnmlaflgENAEVKEMMTTWTL 543
Cdd:cd09601  397 RKGLRKYLKKHAYGNATTDDLWEALQEASGES-----------------------KPLDVKEIMDSWTL 442
PepN COG0308
Aminopeptidase N, contains DUF3458 domain [Amino acid transport and metabolism];
68-623 7.21e-118

Aminopeptidase N, contains DUF3458 domain [Amino acid transport and metabolism];


Pssm-ID: 440077 [Multi-domain]  Cd Length: 609  Bit Score: 373.59  E-value: 7.21e-118
                         10        20        30        40        50        60        70        80
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 194306629  68 RLPSVVIPLHYDLFVHPNLTSLDFVASEKIEVLV-SNATQFIILHSKDLEITNATLQseedsrymkpGKELKVLSypAHE 146
Cdd:COG0308   10 YRPPGYDVTHYDLDLDLDPATTRLSGTATITFTAtEAPLDSLVLDLKGLEVTSVTVD----------GKPLDFTR--DGE 77
                         90       100       110       120       130       140       150       160
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 194306629 147 QIALLVPEKLTPHLKYYVAMDFQAKLGDGFEGFYKSTYRtlgGETRILAVTDFEPTQARMAFPCFDEPLFKANFSIKIRR 226
Cdd:COG0308   78 RLTITLPKPLAPGETFTLEIEYSGKPSNGGEGLYRSGDP---PDGPPYLYTQCEPEGARRWFPCFDHPDDKATFTLTVTV 154
                        170       180       190       200       210       220       230       240
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 194306629 227 ESRHIALSNMPKVKTIELEGGLLEDHFETTVKMSTYLVAYIVCDFHSLSGFTSSGVKVSIYASPDKRNQTHYALQASLKL 306
Cdd:COG0308  155 PAGWVAVSNGNLVSETELGDGRTTWHWADTQPIPTYLFALAAGDYAVVEDTFASGVPLRVYVRPGLADKAKEAFESTKRM 234
                        250       260       270       280       290       300       310       320
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 194306629 307 LDFYEKYFDIYYPLSKLDLIAIPDFAPGAMENWGLITYRETsLLFDpKTSSASDKLWVTRVIAHELAHQWFGNLVTMEWW 386
Cdd:COG0308  235 LDFFEELFGVPYPFDKYDQVAVPDFNFGAMENQGLVTFGEK-VLAD-ETATDADYERRESVIAHELAHQWFGNLVTCADW 312
                        330       340       350       360       370       380       390       400
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 194306629 387 NDIWLKEGFAKYMELIAVNATYPELQFDDYFLNVCFEV-ITKDSLNSSRPISkpAETPTQIQEMFDEVSYNKGACILNML 465
Cdd:COG0308  313 DDLWLNEGFATYMEQLFSEDLYGKDAADRIFVGALRSYaFAEDAGPNAHPIR--PDDYPEIENFFDGIVYEKGALVLHML 390
                        410       420       430       440       450       460       470       480
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 194306629 466 KDFLGEEKFQKGIIQYLKKFSYRNAKNDDLWSSLSNsclesdfTSGgvchsdpkmtsnmlaflgenAEVKEMMTTWTLQK 545
Cdd:COG0308  391 RTLLGDEAFRAGLRLYFARHAGGNATTEDFLAALEE-------ASG--------------------RDLSAFFDQWLYQA 443
                        490       500       510       520       530       540       550       560
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 194306629 546 GIPLLVVK-----QDGCSLRLQQERFlqgvfqedpewralqERYLWHIPLTYSTSSSNVIHRHILKSKTDTlDLPEKTSW 620
Cdd:COG0308  444 GLPTLEVEyeydaDGKVTLTLRQTPP---------------RPHPFHIPLEVGLLGGKLTARTVLLDGEQT-ELVAKPDP 507

                 ...
gi 194306629 621 VKF 623
Cdd:COG0308  508 VLL 510
M1 cd09595
Peptidase M1 family includes the catalytic domains of aminopeptidase N and leukotriene A4 ...
77-499 9.00e-118

Peptidase M1 family includes the catalytic domains of aminopeptidase N and leukotriene A4 hydrolase; The model represents the catalytic domains of M1 peptidase family members including aminopeptidase N (APN) and leukotriene A4 hydrolase (LTA4H). All peptidases in this family bind a single catalytic zinc ion which is tetrahedrally co-ordinated by three amino acid ligands and a water molecule that forms the nucleophile upon activation during catalysis. APN preferentially cleaves neutral amino acids from the N-terminus of oligopeptides and is present in a variety of human tissues and cell types. APN expression is dysregulated in many inflammatory diseases and is enhanced in numerous tumor cells, making it a lead target in the development of anti-cancer and anti-inflammatory drugs. LTA4H is a bifunctional enzyme, possessing an aminopeptidase as well as an epoxide hydrolase activity. The two activities occupy different, but overlapping sites. The activity and physiological relevance of the aminopeptidase in LTA4H is as yet unknown, while the epoxide hydrolase converts leukotriene A4 (LTA4) into leukotriene B4 (LTB4), a potent chemotaxin that is fundamental to the inflammatory response of mammals.


Pssm-ID: 341058 [Multi-domain]  Cd Length: 413  Bit Score: 366.38  E-value: 9.00e-118
                         10        20        30        40        50        60        70        80
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 194306629  77 HYDLFVHPNLTSLDFVASEKIEVLVSNATQFIILHSKDLEITNATLQseedsrymkpGKELKVLSYPAHEQIALLVPEKL 156
Cdd:cd09595    2 HYDLDLDVDFTTKTLNGTETLTVDASQVGRELVLDLVGLTIHSVSVN----------GAAVDFGEREHYDGEKLTIPGPK 71
                         90       100       110       120       130       140       150       160
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 194306629 157 TPHLKYYVAMDFQAKLGDGFEGFYKSTYrtlGGETRILAVTDFEPTQARMAFPCFDEPLFKANFSIKIRRESRHIALSNM 236
Cdd:cd09595   72 PPGQTFTVRISFEAKPSKNLLGWLWEQT---AGKEKPYLFTQFEATHARRIFPCIDHPAVKATFTVTITTPKKDLLASNG 148
                        170       180       190       200       210       220       230       240
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 194306629 237 PKVKTIELEGGLLEDHFETTVKMSTYLVAYIVCDFHSL--SGFTSSGVKVSIYASPDKRNQTHYALQASLKLLDFYEKYF 314
Cdd:cd09595  149 ALVGEETGANGRKTYRFEDTPPIPTYLVAVVVGDLEFKyvTVKSQPRVGLSVYSEPLQVDQAQYAFDATRAALAWFEDYF 228
                        250       260       270       280       290       300       310       320
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 194306629 315 DIYYPLSKLDLIAIPDFAPGAMENWGLITYRETSLLFDPKTssASDKLWVTRVIAHELAHQWFGNLVTMEWWNDIWLKEG 394
Cdd:cd09595  229 GGPYPLPKYDLLAVPDFNSGAMENPGLITFRTTYLLRSKVT--DTGARSIENVIAHELAHQWFGNLVTMRWWNDLWLNEG 306
                        330       340       350       360       370       380       390       400
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 194306629 395 FAKYMELIAVNATYPELQFDDYFLNVCFEVITKDSLNSSRPISKPAETPTQIQEMFDEVSYNKGACILNMLKDFLGEEKF 474
Cdd:cd09595  307 FAVYYENRIMDATFGTSSRHLDQLSGSSDLNTEQLLEDSSPTSTPVRSPADPDVAYDGVTYAKGALVLRMLEELVGEEAF 386
                        410       420
                 ....*....|....*....|....*
gi 194306629 475 QKGIIQYLKKFSYRNAKNDDLWSSL 499
Cdd:cd09595  387 DKGVQAYFNRHKFKNATTDDFIDAL 411
Peptidase_M1 pfam01433
Peptidase family M1 domain; Members of this family are aminopeptidases. The members differ ...
298-500 3.25e-93

Peptidase family M1 domain; Members of this family are aminopeptidases. The members differ widely in specificity, hydrolysing acidic, basic or neutral N-terminal residues. This family includes leukotriene-A4 hydrolase, this enzyme also has an aminopeptidase activity.


Pssm-ID: 426262 [Multi-domain]  Cd Length: 219  Bit Score: 294.20  E-value: 3.25e-93
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 194306629  298 YALQASLKLLDFYEKYFDIYYPLSKLDLIAIPDFAPGAMENWGLITYRETSLLFDPKTSSASDKLWVTRVIAHELAHQWF 377
Cdd:pfam01433   1 YALEITVKLLEFYEDYFNIPYPLPKYDLVALPDFSAGAMENWGLITYRETLLLYDPGNSSTSDKQRVASVIAHELAHQWF 80
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 194306629  378 GNLVTMEWWNDIWLKEGFAKYMELIAVNATYPELQF-DDYFLNVCFEVITKDSLNSSRPISKPAETPTQIQEMFDEVSYN 456
Cdd:pfam01433  81 GNLVTMKWWDDLWLNEGFATYMEYLGTDALFPEWNIwEQFLLDEVQNAMARDALDSSHPITQNVNDPSEIDDIFDAIPYE 160
                         170       180       190       200
                  ....*....|....*....|....*....|....*....|....
gi 194306629  457 KGACILNMLKDFLGEEKFQKGIIQYLKKFSYRNAKNDDLWSSLS 500
Cdd:pfam01433 161 KGASVLRMLETLLGEEVFQKGLRSYLKKFQYGNATTEDLWDALS 204
M1_APN cd09602
Peptidase M1 family including aminopeptidase N catalytic domain; This model represents the ...
71-500 4.38e-86

Peptidase M1 family including aminopeptidase N catalytic domain; This model represents the catalytic domain of bacterial and eukaryotic aminopeptidase N (APN; CD13; alanyl aminopeptidase; EC 3.4.11.2), a type II integral membrane protease belonging to the M1 gluzincin family. APN preferentially cleaves neutral amino acids from the N-terminus of oligopeptides and, in higher eukaryotes, is present in a variety of human tissues and cell types (leukocyte, fibroblast, endothelial and epithelial cells). APN expression is dysregulated in inflammatory diseases such as chronic pain, rheumatoid arthritis, multiple sclerosis, systemic sclerosis, systemic lupus erythematosus, polymyositis/dermatomyosytis and pulmonary sarcoidosis, and is enhanced in tumor cells such as melanoma, renal, prostate, pancreas, colon, gastric and thyroid cancers. It is predominantly expressed on stem cells and on cells of the granulocytic and monocytic lineages at distinct stages of differentiation, thus considered a marker of differentiation. Thus, APN inhibition may lead to the development of anti-cancer and anti-inflammatory drugs. APNs are also present in many pathogenic bacteria and represent potential drug targets. Some APNs have been used commercially, such as one from Lactococcus lactis used in the food industry. APN also serves as a receptor for coronaviruses, although the virus receptor interaction site seems to be distinct from the enzymatic site and aminopeptidase activity is not necessary for viral infection. APNs have also been extensively studied as putative Cry toxin receptors. Cry1 proteins are pore-forming toxins that bind to the midgut epithelial cell membrane of susceptible insect larvae, causing extensive damage. Several different toxins, including Cry1Aa, Cry1Ab, Cry1Ac, Cry1Ba, Cry1Ca and Cry1Fa, have been shown to bind to APNs; however, a direct role of APN in cytotoxicity has been yet to be firmly established.


Pssm-ID: 341065 [Multi-domain]  Cd Length: 440  Bit Score: 283.25  E-value: 4.38e-86
                         10        20        30        40        50        60        70        80
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 194306629  71 SVVIPLHYDLFVhpNLTSLD--FVASEKIEVLVSNATQFIILHSKDLEITNATLQseedsrymkpGKELKVlSYPAHEQI 148
Cdd:cd09602   11 ALISVVSYDLDL--DLTEGAetFRGTVTIRFTLREPGASLFLDFRGGEVKSVTLN----------GRPLDP-SAFDGERI 77
                         90       100       110       120       130       140       150       160
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 194306629 149 ALlvpEKLTPHLKYYVAMDFQA---KLGDGFEGFYKSTYrtlgGETRILavTDFEPTQARMAFPCFDEPLFKANFSIKIR 225
Cdd:cd09602   78 TL---PGLLKAGENTVVVEFTApysSDGEGLHRFVDPAD----GETYLY--TLFEPDDARRVFPCFDQPDLKATFTLTVT 148
                        170       180       190       200       210       220       230       240
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 194306629 226 RESRHIALSNMPKVKTIELEGGLLEdHFETTVKMSTYLVAYIVCDFHSLSgFTSSGVKVSIYAspdKRNQTHYALQASL- 304
Cdd:cd09602  149 APADWTVISNGPETSTEEAGGRKRW-RFAETPPLSTYLFAFVAGPYHRVE-DEHDGIPLGLYC---RESLAEYERDADEi 223
                        250       260       270       280       290       300       310       320
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 194306629 305 -----KLLDFYEKYFDIYYPLSKLDLIAIPDFAPGAMENWGLITYRETSLLFDPKTssASDKLWVTRVIAHELAHQWFGN 379
Cdd:cd09602  224 fevtkQGLDFYEDYFGIPYPFGKYDQVFVPEFNFGAMENPGAVTFRESYLFREEPT--RAQRLRRANTILHEMAHMWFGD 301
                        330       340       350       360       370       380       390       400
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 194306629 380 LVTMEWWNDIWLKEGFAKYMeliAVNATYPELQFDDYFLNvcFEVITK------DSLNSSRPISKPAETPTQIQEMFDEV 453
Cdd:cd09602  302 LVTMKWWDDLWLNESFADFM---AAKALAEATPFTDAWLT--FLLRRKpwayraDQLPTTHPIAQDVPDLEAAGSNFDGI 376
                        410       420       430       440
                 ....*....|....*....|....*....|....*....|....*..
gi 194306629 454 SYNKGACILNMLKDFLGEEKFQKGIIQYLKKFSYRNAKNDDLWSSLS 500
Cdd:cd09602  377 TYAKGASVLKQLVALVGEEAFRAGLREYFKKHAYGNATLDDLIAALD 423
ERAP1_C pfam11838
ERAP1-like C-terminal domain; This large domain is composed of 16 alpha helices organized as 8 ...
620-938 2.81e-84

ERAP1-like C-terminal domain; This large domain is composed of 16 alpha helices organized as 8 HEAT-like repeats. This domain forms a concave face that faces towards the active site of the peptidase.


Pssm-ID: 463368 [Multi-domain]  Cd Length: 316  Bit Score: 274.15  E-value: 2.81e-84
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 194306629  620 WVKFNVDSNGYYIVHYEGHGWDQLITQLNqnHTLLRPKDRVGLIHDVFQLVGAGRLTLDKALDMTYYLQHETSSPALLEG 699
Cdd:pfam11838   1 WVKLNADDTGYYRVNYDPESLAALLEQLL--SKVLSPLDRAGLIDDAFALARAGELSTSDALDLVLAYLNETDYVVWSAA 78
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 194306629  700 LSYLESFYHMMDRrniSDISENLKRYLLQYFKPVIDRQSWSDKG--SVWDRMLRSALLKLACDLNHAPCIQKAAELFSQW 777
Cdd:pfam11838  79 LSQLSTLRSLLSA---DPEYEALKAFLRKLLSPLAEKLGWEAPPgeSHLDRQLRALLLSAACSAGDPECVAEAKKLFDAW 155
                         170       180       190       200       210       220       230       240
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 194306629  778 MEssGKLNIPTDVLKIVYSVGAQ--TTAGWNYLLEQYELSMSSAEQNKILYALSTSKHQEKLLKLIELGMEGKVIKTQNL 855
Cdd:pfam11838 156 LD--GDDAIPPDLRWAVYCAAVAngGEAEWDALLERYRDTTSPSEKERALRALAATPDPELLQRALELALDSDEVRNQDL 233
                         250       260       270       280       290       300       310       320
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 194306629  856 AALLHAIARRPKGQQLAWDFVRENWTHLLKKFDLGSYdIRMIISGTTAHFSSKDKLQEVKLFFESLEAQGSHLdIFQTVL 935
Cdd:pfam11838 234 RAVIAGLASNPAGRDLAWDFVKENWDALVKRLGGGSS-LGRLVKGLTPSFSTEEELDEVEAFFADKDTPGLRR-ALAQAL 311

                  ...
gi 194306629  936 ETI 938
Cdd:pfam11838 312 ETI 314
M1_APN_like cd09603
Peptidase M1 family similar to aminopeptidase N catalytic domain; This family contains mostly ...
76-495 6.05e-64

Peptidase M1 family similar to aminopeptidase N catalytic domain; This family contains mostly bacterial and some archaeal M1 peptidases with smilarity to the catalytic domain of aminopeptidase N (APN; CD13; alanyl aminopeptidase; EC 3.4.11.2), a type II integral membrane protease belonging to the M1 gluzincin family. APN preferentially cleaves neutral amino acids from the N-terminus of oligopeptides and, in higher eukaryotes, is present in a variety of human tissues and cell types (leukocyte, fibroblast, endothelial and epithelial cells). APN expression is dysregulated in inflammatory diseases such as chronic pain, rheumatoid arthritis, multiple sclerosis, systemic sclerosis, systemic lupus erythematosus, polymyositis/dermatomyosytis and pulmonary sarcoidosis, and is enhanced in tumor cells such as melanoma, renal, prostate, pancreas, colon, gastric and thyroid cancers. It is predominantly expressed on stem cells and on cells of the granulocytic and monocytic lineages at distinct stages of differentiation, thus considered a marker of differentiation. Thus, APN inhibition may lead to the development of anti-cancer and anti-inflammatory drugs. APNs are also present in many pathogenic bacteria and represent potential drug targets. Some APNs have been used commercially, such as one from Lactococcus lactis used in the food industry. APN also serves as a receptor for coronaviruses, although the virus receptor interaction site seems to be distinct from the enzymatic site and aminopeptidase activity is not necessary for viral infection. APNs have also been extensively studied as putative Cry toxin receptors. Cry1 proteins are pore-forming toxins that bind to the midgut epithelial cell membrane of susceptible insect larvae, causing extensive damage. Several different toxins, including Cry1Aa, Cry1Ab, Cry1Ac, Cry1Ba, Cry1Ca and Cry1Fa, have been shown to bind to APNs; however, a direct role of APN in cytotoxicity has been yet to be firmly established.


Pssm-ID: 341066 [Multi-domain]  Cd Length: 410  Bit Score: 221.69  E-value: 6.05e-64
                         10        20        30        40        50        60        70        80
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 194306629  76 LHYDLFVHPNLTSLDFVASEKIEVLVSNATQFIILHSKDLEITNATLQSEEDSRYMKPGKELKV---LSYPAHEQIALLV 152
Cdd:cd09603    4 LHYDLDLDYDPATKSLSGTATITFRATQDLDSLQLDLVGLTVSSVTVDGVPAAFFTHDGDKLVItlpRPLAAGETFTVTV 83
                         90       100       110       120       130       140       150       160
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 194306629 153 pekltphlkYYVAmdfQAKLGDGFEGFYKSTYRTLGGetrilAVTDFEPTQARMAFPCFDEPLFKANFSIKIRRESRHIA 232
Cdd:cd09603   84 ---------RYSG---KPRPAGYPPGDGGGWEEGDDG-----VWTAGQPEGASTWFPCNDHPDDKATYDITVTVPAGLTV 146
                        170       180       190       200       210       220       230       240
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 194306629 233 LSNMPKVKTIELEGGLLEDHFETTVKMSTYLVAYIVCDFHSLSGFTSSGVKVSIYASPDKRNQTHYALQASLKLLDFYEK 312
Cdd:cd09603  147 VSNGRLVSTTTNGGGTTTWHWKMDYPIATYLVTLAVGRYAVVEDGSGGGIPLRYYVPPGDAAKAKASFARTPEMLDFFEE 226
                        250       260       270       280       290       300       310       320
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 194306629 313 YFDIYyPLSKLDLIAIPDFApGAMENWGLITYRETSLLFDPKTssasdklwvTRVIAHELAHQWFGNLVTMEWWNDIWLK 392
Cdd:cd09603  227 LFGPY-PFEKYGQVVVPDLG-GGMEHQTATTYGNNFLNGDRGS---------ERLIAHELAHQWFGDSVTCADWADIWLN 295
                        330       340       350       360       370       380       390       400
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 194306629 393 EGFAKYMELIAVNATYPELQFDDYFLNvcfeviTKDSLNSSRPISKPaetPTQIQEMFDEVSYNKGACILNMLKDFLGEE 472
Cdd:cd09603  296 EGFATYAEWLWSEHKGGADAYRAYLAG------QRQDYLNADPGPGR---PPDPDDLFDRDVYQKGALVLHMLRNLLGDE 366
                        410       420
                 ....*....|....*....|...
gi 194306629 473 KFQKGIIQYLKKFSYRNAKNDDL 495
Cdd:cd09603  367 AFFAALRAYLARYAHGNVTTEDF 389
pepN_strep_liv TIGR02412
aminopeptidase N, Streptomyces lividans type; This family is a subset of the members of the ...
197-503 8.50e-60

aminopeptidase N, Streptomyces lividans type; This family is a subset of the members of the zinc metallopeptidase family M1 (pfam01433), with a single member characterized in Streptomyces lividans 66 and designated aminopeptidase N. The spectrum of activity may differ somewhat from the aminopeptidase N clade of E. coli and most other Proteobacteria, well separated phylogenetically within the M1 family. The M1 family also includes leukotriene A-4 hydrolase/aminopeptidase (with a bifunctional active site).


Pssm-ID: 274121 [Multi-domain]  Cd Length: 831  Bit Score: 220.05  E-value: 8.50e-60
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 194306629  197 TDFEPTQARMAFPCFDEPLFKANFSIKIRRESRHIALSNMPKVKTIELEGGLLEDhFETTVKMSTYLVAYIVCDFHSLSG 276
Cdd:TIGR02412 122 TQFEPADARRVFAVFDQPDLKANFKFSVKAPEDWTVISNSRETDVTPEPADRRWE-FPETPKLSTYLTAVAAGPYHSVQD 200
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 194306629  277 fTSSGVKVSIYASPDKRNQ--THYALQASLKLLDFYEKYFDIYYPLSKLDLIAIPDFAPGAMENWGLITYRETSLLFDPK 354
Cdd:TIGR02412 201 -ESRSYPLGIYARRSLAQYldADAIFTITRQGLAFFHRKFGYPYPFKKYDQIFVPEFNAGAMENAGCVTFAENFLHRAEA 279
                         170       180       190       200       210       220       230       240
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 194306629  355 TSSASDKLwvTRVIAHELAHQWFGNLVTMEWWNDIWLKEGFAKYME-LIAVNATYPELQFDDYFLNVCFEVITKDSLNSS 433
Cdd:TIGR02412 280 TRAEKENR--AGVILHEMAHMWFGDLVTMRWWNDLWLNESFAEYMGtLASAEATEYTDAWTTFAAQGKQWAYEADQLPTT 357
                         250       260       270       280       290       300       310
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 194306629  434 RPISKPAETPTQIQEMFDEVSYNKGACILNMLKDFLGEEKFQKGIIQYLKKFSYRNAKNDDLWSSLSNSC 503
Cdd:TIGR02412 358 HPIVADVADLADALSNFDGITYAKGASVLKQLVAWVGEEAFFAGVNAYFKRHAFGNATLDDLIDSLAKAS 427
Peptidase_M1_N pfam17900
Peptidase M1 N-terminal domain; This domain is found at the N-terminus of aminopeptidases from ...
75-263 9.87e-52

Peptidase M1 N-terminal domain; This domain is found at the N-terminus of aminopeptidases from the M1 family.


Pssm-ID: 465557 [Multi-domain]  Cd Length: 186  Bit Score: 179.46  E-value: 9.87e-52
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 194306629   75 PLHYDLFVHPNLTSLDFVASEKIEVLVSNATQFIILHSKDLEITNATLQSEEDSrymKPGKELKVLSYPAHEQIALLVPE 154
Cdd:pfam17900   2 PEHYDLDLKIDLKNFTFSGSVTITLQLNNATNVIVLHASDLTIRSISLSDEVTS---DGVPADFTEDQKDGEKLTIVLPE 78
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 194306629  155 KLTPHLKYYVAMDFQAKLGDGFEGFYKSTYrTLGGETRILAVTDFEPTQARMAFPCFDEPLFKANFSIKIRRESRHIALS 234
Cdd:pfam17900  79 TLNQTGPYTLEIEYSGELNDSMTGFYRSTY-TDNGEKKVLVTTQFEPTDARSAFPCFDEPSVKATFTISIIHPKDYTALS 157
                         170       180
                  ....*....|....*....|....*....
gi 194306629  235 NMPKVKTIELEGGLLEDHFETTVKMSTYL 263
Cdd:pfam17900 158 NMPVIASEPLENGWVITTFEQTPKMSTYL 186
M1_APN cd09600
Peptidase M1 family, including aminopeptidase N catalytic domain; This model represents the ...
233-485 3.99e-32

Peptidase M1 family, including aminopeptidase N catalytic domain; This model represents the catalytic domain of aminopeptidase N (APN; CD13; alanyl aminopeptidase; EC 3.4.11.2), a type II integral membrane protease belonging to the M1 gluzincin family. It includes bacterial-type alanyl aminopeptidases as well as PfA-M1 aminopeptidase (Plasmodium falciparum-type). APN preferentially cleaves neutral amino acids from the N-terminus of oligopeptides and, in higher eukaryotes, is present in a variety of human tissues and cell types (leukocyte, fibroblast, endothelial and epithelial cells). APN expression is dysregulated in inflammatory diseases such as chronic pain, rheumatoid arthritis, multiple sclerosis, systemic sclerosis, systemic lupus erythematosus, polymyositis/dermatomyosytis and pulmonary sarcoidosis, and is enhanced in tumor cells such as melanoma, renal, prostate, pancreas, colon, gastric and thyroid cancers. It is predominantly expressed on stem cells and on cells of the granulocytic and monocytic lineages at distinct stages of differentiation, thus considered a marker of differentiation. Thus, APN inhibition may lead to the development of anti-cancer and anti-inflammatory drugs. APNs are also present in many pathogenic bacteria and represent potential drug targets. Some APNs have been used commercially, such as one from Lactococcus lactis used in the food industry. APN also serves as a receptor for coronaviruses, although the virus receptor interaction site seems to be distinct from the enzymatic site and aminopeptidase activity is not necessary for viral infection. APNs have also been extensively studied as putative Cry toxin receptors. Cry1 proteins are pore-forming toxins that bind to the midgut epithelial cell membrane of susceptible insect larvae, causing extensive damage. Several different toxins, including Cry1Aa, Cry1Ab, Cry1Ac, Cry1Ba, Cry1Ca and Cry1Fa, have been shown to bind to APNs; however, a direct role of APN in cytotoxicity has been yet to be firmly established.


Pssm-ID: 341063 [Multi-domain]  Cd Length: 434  Bit Score: 130.33  E-value: 3.99e-32
                         10        20        30        40        50        60        70        80
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 194306629 233 LSNMPKVKTIELEGGLLEDHFETTVKMSTYLVAYIVCDFHSLSGF--TSSG--VKVSIYASPDKRNQTHYALQaSLKL-L 307
Cdd:cd09600  149 LSNGNLIEEGELPNGRHFAVWEDPFPKPSYLFALVAGDLGSVEDTftTKSGrkVKLRIYVEPGNEDKCHHAME-SLKKaM 227
                         90       100       110       120       130       140       150       160
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 194306629 308 DFYEKYFDIYYPLSKLDLIAIPDFAPGAMENWGLITYRETSLLFDPKTSSASDKLWVTRVIAHELAHQWFGNLVTMEWWN 387
Cdd:cd09600  228 KWDEERFGLEYDLDLFNIVAVDDFNMGAMENKGLNIFNSKYVLADPETATDADYERIESVIAHEYFHNWTGNRVTCRDWF 307
                        170       180       190       200       210       220       230       240
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 194306629 388 DIWLKEG--------FAKYMELIAVN-----ATYPELQFDDyflnvcfevitkDSLNSSRPIsKPAE--------TPTqi 446
Cdd:cd09600  308 QLSLKEGltvfrdqeFSADMNSRAVKriedvRRLRSAQFPE------------DAGPMAHPI-RPDSyieinnfyTVT-- 372
                        250       260       270
                 ....*....|....*....|....*....|....*....
gi 194306629 447 qemfdevSYNKGACILNMLKDFLGEEKFQKGIIQYLKKF 485
Cdd:cd09600  373 -------VYEKGAEVIRMLHTLLGEEGFRKGMDLYFERH 404
M1_APN_like cd09604
Peptidase M1 family similar to aminopeptidase N catalytic domain; This family contains ...
270-503 3.43e-27

Peptidase M1 family similar to aminopeptidase N catalytic domain; This family contains bacterial M1 peptidases with smilarity to the catalytic domain of aminopeptidase N (APN; CD13; alanyl aminopeptidase; EC 3.4.11.2), a type II integral membrane protease belonging to the M1 gluzincin family. APN preferentially cleaves neutral amino acids from the N-terminus of oligopeptides and, in higher eukaryotes, is present in a variety of human tissues and cell types (leukocyte, fibroblast, endothelial and epithelial cells). APN expression is dysregulated in inflammatory diseases such as chronic pain, rheumatoid arthritis, multiple sclerosis, systemic sclerosis, systemic lupus erythematosus, polymyositis/dermatomyosytis and pulmonary sarcoidosis, and is enhanced in tumor cells such as melanoma, renal, prostate, pancreas, colon, gastric and thyroid cancers. It is predominantly expressed on stem cells and on cells of the granulocytic and monocytic lineages at distinct stages of differentiation, thus considered a marker of differentiation. Thus, APN inhibition may lead to the development of anti-cancer and anti-inflammatory drugs. APNs are also present in many pathogenic bacteria and represent potential drug targets. Some APNs have been used commercially, such as one from Lactococcus lactis used in the food industry. APN also serves as a receptor for coronaviruses, although the virus receptor interaction site seems to be distinct from the enzymatic site and aminopeptidase activity is not necessary for viral infection. APNs have also been extensively studied as putative Cry toxin receptors. Cry1 proteins are pore-forming toxins that bind to the midgut epithelial cell membrane of susceptible insect larvae, causing extensive damage. Several different toxins, including Cry1Aa, Cry1Ab, Cry1Ac, Cry1Ba, Cry1Ca and Cry1Fa, have been shown to bind to APNs; however, a direct role of APN in cytotoxicity has been yet to be firmly established.


Pssm-ID: 341067 [Multi-domain]  Cd Length: 440  Bit Score: 115.84  E-value: 3.43e-27
                         10        20        30        40        50        60        70        80
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 194306629 270 DFHSLSGfTSSGVKVSIYASPDKRNQTHYALQASLKLLDFYEKYFdIYYPLSKLDLIAiPDFAPGAMENWGLITYRetsl 349
Cdd:cd09604  211 DFVVDAA-TVDGVTVNVYYLPENAEAAERALEYAKDALEFFSEKF-GPYPYPELDVVQ-GPFGGGGMEYPGLVFIG---- 283
                         90       100       110       120       130       140       150       160
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 194306629 350 lfdpkTSSASDKLWVTRVIAHELAHQWFGNLVTmewwNDI----WLKEGFAKYMELIAVNATYPELQFDDYFLNVCFEVI 425
Cdd:cd09604  284 -----SRLYDPKRSLEGVVVHEIAHQWFYGIVG----NDErrepWLDEGLATYAESLYLEEKYGKEAADELLGRRYYRAY 354
                        170       180       190       200       210       220       230
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*...
gi 194306629 426 TKdslNSSRPISKPAETPTQIQEMFDeVSYNKGACILNMLKDFLGEEKFQKGIIQYLKKFSYRNAKNDDLWSSLSNSC 503
Cdd:cd09604  355 AR---GPGGPINLPLDTFPDGSYYSN-AVYSKGALFLEELREELGDEAFDKALREYYRRYKFKHPTPEDFFRTAEEVS 428
leuko_A4_hydro TIGR02411
leukotriene A-4 hydrolase/aminopeptidase; Members of this family represent a distinctive ...
78-499 3.45e-26

leukotriene A-4 hydrolase/aminopeptidase; Members of this family represent a distinctive subset within the zinc metallopeptidase family M1 (pfam01433). The majority of the members of pfam01433 are aminopeptidases, but the sequences in this family for which the function is known are leukotriene A-4 hydrolase. A dual epoxide hydrolase and aminopeptidase activity at the same active site is indicated. The physiological substrate for aminopeptidase activity is not known.


Pssm-ID: 274120 [Multi-domain]  Cd Length: 602  Bit Score: 114.87  E-value: 3.45e-26
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 194306629   78 YDLFVHPNLT---SLDFVASE-------KIEVLVSNATQfIILHSKDLEITNATLQSEEDSRYMKPGKElkvlsyPAHEQ 147
Cdd:TIGR02411   8 YKDFRTSHTDlnlSVDFTKRKlsgsvtfTLKSLTDNLNK-LVLDTSYLDIQKVTINGLPADFAIGERKE------PLGSP 80
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 194306629  148 IALLVPEKLTPHLKYYVAMDFQAKLGDGFEGFYKSTyRTLGGETRILaVTDFEPTQARMAFPCFDEPLFKANFSIKIrrE 227
Cdd:TIGR02411  81 LTISLPIATSKNDEFVLNISFSTTPKCTALQWLNPE-QTSGKKHPYL-FSQCQAIHARSLFPCQDTPSVKSTYTAEV--E 156
                         170       180       190       200       210       220       230       240
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 194306629  228 SRHIAL-SNMPKVKTIELEGGLLedhFETTVKMSTYLVAYIVCDFHSlsgfTSSGVKVSIYASPDK--------RNQTHY 298
Cdd:TIGR02411 157 SPLPVLmSGIRDGETSNDPGKYL---FKQKVPIPAYLIAIASGDLAS----APIGPRSTVYSEPEQlekcqyefENDTEK 229
                         250       260       270       280       290       300       310       320
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 194306629  299 ALQASLKLLDFYE-KYFDIyyplskldLIAIPDFAPGAMENwglityreTSLLFDPKTSSASDKLWVtRVIAHELAHQWF 377
Cdd:TIGR02411 230 FIKTAEDLIFPYEwGQYDL--------LVLPPSFPYGGMEN--------PNLTFATPTLIAGDRSNV-DVIAHELAHSWS 292
                         330       340       350       360       370       380       390       400
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 194306629  378 GNLVTMEWWNDIWLKEGFAKYMELIAVNATYPELQFDdyflnvcFEVIT--KDSLNSSRPISKPAETPTQIQEM------ 449
Cdd:TIGR02411 293 GNLVTNCSWEHFWLNEGWTVYLERRIIGRLYGEKTRH-------FSALIgwGDLQESVKTLGETPEFTKLVVDLkdndpd 365
                         410       420       430       440       450
                  ....*....|....*....|....*....|....*....|....*....|...
gi 194306629  450 --FDEVSYNKGACILNMLKDFLG-EEKFQKGIIQYLKKFSYRNAKNDDLWSSL 499
Cdd:TIGR02411 366 daFSSVPYEKGFNFLFYLEQLLGgPAEFDPFLRHYFKKFAYKSLDTYQFKDAL 418
M1_LTA4H cd09599
Peptidase M1 family including Leukotriene A4 hydrolase catalytic domain; This model represents ...
76-488 3.70e-25

Peptidase M1 family including Leukotriene A4 hydrolase catalytic domain; This model represents the N-terminal catalytic domain of leukotriene A4 hydrolase (LTA4H; E.C. 3.3.2.6) and the close homolog cold-active aminopeptidase (Colwellia psychrerythraea-type peptidase; ColAP), both members of the aminopeptidase M1 family. LTA4H is a bifunctional enzyme, possessing an aminopeptidase as well as an epoxide hydrolase activity. The two activities occupy different, but overlapping sites. The activity and physiological relevance of the aminopeptidase is poorly understood while the epoxide hydrolase converts leukotriene A4 (LTA4) into leukotriene B4 (LTB4), a potent chemotaxin that is fundamental to the inflammatory response of mammals. It accepts a variety of substrates, including some opioid, di- and tripeptides, as well as chromogenic aminoacyl-p-nitroanilide derivatives. The aminopeptidase activity of LTA4H is possibly involved in the processing of peptides related to inflammation and host defense. Kinetic analysis shows that LTA4H hydrolyzes arginyl tripeptides with high efficiency and specificity, indicating its function as an arginyl aminopeptidase. Thermodynamic characterization using different biophysical methods shows that structurally distinct inhibitors of the LTA4H occupy different regions of the binding site; while some (RB202, ARM1 and SC57461A) bind to the hydrophobic hydrolase side, both bestatin and captopril are located at the hydrophilic peptidase side. LTB4H overexpression is associated with different pathological conditions and diseases such as cystic fibrosis, coronary heart disease, sepsis, shock, connective tissue disease, and chronic obstructive pulmonary disease. It is also overexpressed in certain human cancers, and has been identified as a functionally important target for mediating anticancer properties of resveratrol, a well-known red wine polyphenolic compound with cancer chemopreventive activity.


Pssm-ID: 341062 [Multi-domain]  Cd Length: 442  Bit Score: 109.85  E-value: 3.70e-25
                         10        20        30        40        50        60        70        80
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 194306629  76 LHYDLFVHPNLTSLDFVASEKIEVLVSNATQfIILHSKDLEITNATLQSEEDSRYmkpgkELKVLSYPAHEQIALLVPEK 155
Cdd:cd09599   16 LDLDLTVDFDKKTISGSATLTLEVLQDGADE-LVLDTRDLDISSVTVNGGKELKF-----ELGPRDPVLGSALTITLPSP 89
                         90       100       110       120       130       140       150       160
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 194306629 156 LTPHLKYYVAMDfqaklgdgfegfYKSTYR-----------TLGGETRILavtdF---EPTQARMAFPCFDEPLFKANFS 221
Cdd:cd09599   90 LAKGDTFKVKIE------------YSTTPQatalqwltpeqTAGKKHPYL----FtqcQAIHARSLFPCQDTPSVKSTYS 153
                        170       180       190       200       210       220       230       240
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 194306629 222 IKIRRESRHIAL---SNMPKvktiELEGGLLEDHFETTVKMSTYLVAYIVCDFhslsGFTSSGVKVSIYASPDKRNQTHY 298
Cdd:cd09599  154 ATVTVPKGLTALmsaLRTGE----KEEAGTGTYTFEQPVPIPSYLIAIAVGDL----ESREIGPRSGVWAEPSVVDAAAE 225
                        250       260       270       280       290       300       310       320
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 194306629 299 ALQASLKLLDFYEKYFdIYYPLSKLDLIAIPDFAP-GAMENwGLITYRETSLLfdpktssASDKLWVTrVIAHELAHQWF 377
Cdd:cd09599  226 EFADTEKFLKAAEKLY-GPYVWGRYDLLVLPPSFPyGGMEN-PCLTFATPTLI-------AGDRSLVD-VIAHEIAHSWS 295
                        330       340       350       360       370       380       390       400
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 194306629 378 GNLVTMEWWNDIWLKEGFAKYMELIAVNATYPElqfdDYFlnvCFEVIT-------------KDSLNSSRPISKPAETPt 444
Cdd:cd09599  296 GNLVTNANWEHFWLNEGFTVYLERRILERLYGE----EYR---QFEAILgwkdlqesikefgEDPPYTLLVPDLKGVDP- 367
                        410       420       430       440
                 ....*....|....*....|....*....|....*....|....
gi 194306629 445 qiQEMFDEVSYNKGACILNMLKDFLGEEKFQKGIIQYLKKFSYR 488
Cdd:cd09599  368 --DDAFSSVPYEKGFQFLYYLEQLGGREVFDPFLRAYFKKFAFQ 409
pepN PRK14015
aminopeptidase N; Provisional
233-485 5.47e-12

aminopeptidase N; Provisional


Pssm-ID: 237585 [Multi-domain]  Cd Length: 875  Bit Score: 69.77  E-value: 5.47e-12
                         10        20        30        40        50        60        70        80
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 194306629 233 LSNMPKVKTIELEGGLledHFET----TVKMStYLVAYIVCDFHSLS-GF-TSSG--VKVSIYASPDKRNQTHYALQaSL 304
Cdd:PRK14015 161 LSNGNLVESGELPDGR---HWATwedpFPKPS-YLFALVAGDLDVLEdTFtTRSGreVALEIYVEPGNLDKCDHAMD-SL 235
                         90       100       110       120       130       140       150       160
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 194306629 305 K---LLDfyEKYFDIYYPLSKLDLIAIPDFAPGAMENWGL-I---TYretsLLFDPKTSSASDKLWVTRVIAHELAHQWF 377
Cdd:PRK14015 236 KksmKWD--EERFGLEYDLDIFMIVAVDDFNMGAMENKGLnIfnsKY----VLADPETATDADYERIESVIAHEYFHNWT 309
                        170       180       190       200       210       220       230       240
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 194306629 378 GNLVTMEWWNDIWLKEGFAKY--------MELIAVN-----ATYPELQFDDyflnvcfevitkDSLNSSRPISkpaetPT 444
Cdd:PRK14015 310 GNRVTCRDWFQLSLKEGLTVFrdqefsadLGSRAVKriedvRVLRAAQFAE------------DAGPMAHPVR-----PD 372
                        250       260       270       280
                 ....*....|....*....|....*....|....*....|....
gi 194306629 445 QIQEM--FDEVS-YNKGACILNMLKDFLGEEKFQKGIIQYLKKF 485
Cdd:PRK14015 373 SYIEInnFYTATvYEKGAEVIRMLHTLLGEEGFRKGMDLYFERH 416
M1_like_TAF2 cd09839
TATA binding protein (TBP) associated factor 2; This family includes TATA binding protein (TBP) ...
278-399 2.76e-11

TATA binding protein (TBP) associated factor 2; This family includes TATA binding protein (TBP) associated factor 2 (TAF2, TBP-associated factor TAFII150, transcription initiation factor TFIID subunit 2, RNA polymerase II TBP-associated factor subunit B), and has homology to the M1 gluzincin family. TAF2 is part of the TFIID multidomain subunit complex essential for transcription of most protein-encoded genes by RNA polymerase II. TAF2 is known to interact with the initiator element (Inr) found at the transcription start site of many genes, thus possibly playing a key role in promoter binding as well as start-site selection. Image analysis has shown TAF2 to form a complex with TAF1 and TBP, inferring its role in promoter recognition. Peptidases in the M1 family bind a single catalytic zinc ion which is tetrahedrally co-ordinated by three amino acid ligands and a water molecule that forms the nucleophile on activation during catalysis. TAF2, however, lacks these active site residues.


Pssm-ID: 341074 [Multi-domain]  Cd Length: 531  Bit Score: 67.25  E-value: 2.76e-11
                         10        20        30        40        50        60        70        80
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 194306629 278 TSSGVKVSIYASPDK----RNQTHYALQAslklLDFYEKYFdIYYPLSKLDLI----AIPDFAPGAmenwGLITYrETSL 349
Cdd:cd09839  292 GSSAVEVTGFCLPGRleelRNTCSFLHKA----MDFFEEEY-GSYPFSSYKQVfvddLPEDVSSFA----SLSIC-SSRL 361
                         90       100       110       120       130
                 ....*....|....*....|....*....|....*....|....*....|.
gi 194306629 350 LFDPKtssASDKLW-VTRVIAHELAHQWFGNLVTMEWWNDIWLKEGFAKYM 399
Cdd:cd09839  362 LYPPD---IIDQAYeTRRKLAHALASQWFGINIIPKTWSDTWLVIGIAGYM 409
GluZincin cd09594
Gluzincin Peptidase family (thermolysin-like proteinases, TLPs) which includes peptidases M1, ...
304-403 1.22e-06

Gluzincin Peptidase family (thermolysin-like proteinases, TLPs) which includes peptidases M1, M2, M3, M4, M13, M32 and M36 (fungalysins); The Gluzincin family (thermolysin-like peptidases or TLPs) includes several zinc-dependent metallopeptidases such as M1, M2, M3, M4, M13, M32, M36 peptidases (MEROPS classification), which contain the HEXXH motif as part of their active site. Peptidases in this family bind a single catalytic zinc ion which is tetrahedrally co-ordinated by three amino acid ligands and a water molecule that forms the nucleophile on activation during catalysis. The M1 family includes aminopeptidase N (APN) and leukotriene A4 hydrolase (LTA4H). APN preferentially cleaves neutral amino acids from the N-terminus of oligopeptides and is present in a variety of human tissues and cell types. LTA4H is a bifunctional enzyme, possessing an aminopeptidase as well as an epoxide hydrolase activity such that the two activities occupy different, but overlapping sites. The M3_like peptidases include the M2_ACE, M3 or neurolysin-like family (subfamilies M3B_PepF and M3A) and M32_Taq peptidases. The M2 peptidase angiotensin converting enzyme (ACE, EC 3.4.15.1) catalyzes the conversion of decapeptide angiotensin I to the potent vasopressor octapeptide angiotensin II. ACE is a key component of the renin-angiotensin system that regulates blood pressure, thus ACE inhibitors are important for the treatment of hypertension. M3A includes thimet oligopeptidase (TOP; endopeptidase 3.4.24.15), neurolysin (3.4.24.16), and the mitochondrial intermediate peptidase; and M3B includes oligopeptidase F. The M32 family includes eukaryotic enzymes from protozoa Trypanosoma cruzi, a causative agent of Chagas' disease, and from Leishmania major, a parasite that causes leishmaniasis, making these enzymes attractive targets for drug development. The M4 family includes secreted protease thermolysin (EC 3.4.24.27), pseudolysin, aureolysin, and neutral protease as well as bacillolysin (EC 3.4.24.28) that degrade extracellular proteins and peptides for bacterial nutrition, especially prior to sporulation. Thermolysin is widely used as a nonspecific protease to obtain fragments for peptide sequencing as well as in production of the artificial sweetener aspartame. The M13 family includes neprilysin (EC 3.4.24.11) and endothelin-converting enzyme I (ECE-1, EC 3.4.24.71), which fulfill a broad range of physiological roles due to the greater variation in the S2' subsite allowing substrate specificity and are prime therapeutic targets for selective inhibition. The peptidase M36 fungalysin family includes endopeptidases from pathogenic fungi. Fungalysin hydrolyzes extracellular matrix proteins such as elastin and keratin. Aspergillus fumigatus causes the pulmonary disease aspergillosis by invading the lungs of immuno-compromised animals and secreting fungalysin that possibly breaks down proteinaceous structural barriers.


Pssm-ID: 341057 [Multi-domain]  Cd Length: 105  Bit Score: 47.86  E-value: 1.22e-06
                         10        20        30        40        50        60        70        80
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 194306629 304 LKLLDFYEKYF---DIYYPLS-KLDLIAIPDFAPGAMENwGLITYreTSLLFDPKTSSASDKLwVTRVIAHELAHQWFGN 379
Cdd:cd09594    5 HETYKYYEELLgrtSFRYPVSpIYSLLVYPAYVEVNAYN-AMWIP--STNIFYGAGILDTLSG-TIDVLAHELTHAFTGQ 80
                         90       100
                 ....*....|....*....|....*
gi 194306629 380 LVTMEW-WNDIWLKEGFAKYMELIA 403
Cdd:cd09594   81 FSNLMYsWSSGWLNEGISDYFGGLV 105
Peptidase_MA_2 pfam13485
Peptidase MA superfamily;
357-490 1.65e-05

Peptidase MA superfamily;


Pssm-ID: 290220  Cd Length: 247  Bit Score: 47.33  E-value: 1.65e-05
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 194306629  357 SASDKLWVTRVIAHELAHQwFGNLVTMEWWNDI--WLKEGFakymeliavnATYPELQFDDYFLNVCFEVITKDSLNSSR 434
Cdd:pfam13485  59 ASSAIDWGKRAITHELAHK-VTGQITANPYGDIptWLNEGI----------SMYAEGNLDALYVNFLIQAIDLDKLISVQ 127
                          90       100       110       120       130
                  ....*....|....*....|....*....|....*....|....*....|....*.
gi 194306629  435 PISKPAETPTQIQEMfdevSYNKGACILNMLKDFLGEEKFQKGIIQYLKKFSYRNA 490
Cdd:pfam13485 128 SLCSPFSADPADAYL----SYAESFHIVKYLIDNYGEDKFSDLLEEFAEGAGADEA 179
 
Blast search parameters
Data Source: Precalculated data, version = cdd.v.3.21
Preset Options:Database: CDSEARCH/cdd   Low complexity filter: no  Composition Based Adjustment: yes   E-value threshold: 0.01

References:

  • Wang J et al. (2023), "The conserved domain database in 2023", Nucleic Acids Res.51(D)384-8.
  • Lu S et al. (2020), "The conserved domain database in 2020", Nucleic Acids Res.48(D)265-8.
  • Marchler-Bauer A et al. (2017), "CDD/SPARCLE: functional classification of proteins via subfamily domain architectures.", Nucleic Acids Res.45(D)200-3.
Help | Disclaimer | Write to the Help Desk
NCBI | NLM | NIH